A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

NCT ID: NCT07227831

Last Updated: 2025-11-13

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-28
• Study Completion Date: 2028-05-22

Brief Summary

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are:

• will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer
• the long term safety and tolerability of the TheraBionic P1 device
• assessment of how the disease responded to the TheraBionic P1 device

Conditions

HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Advanced Breast Cancer; Metastatic Breast Cancer

Keywords

therabionic

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TheraBionic P1 device

Self administered Amplitude-modulated electromagnetic fields three times daily

Group Type: EXPERIMENTAL

TheraBionic P1

Intervention Type: DEVICE

Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening

Interventions

TheraBionic P1

Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Participant must have locally advanced/unresectable or metastatic Hormone Receptor (HR) positive, Human Epidermal growth factor receptor 2 (HER2) negative breast cancer as defined by the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (estrogen receptor [ER] and/or progesterone receptor [PR] >1% and HER2 negative by immunohistochemistry [IHC] and/or fluorescent in situ hybridization [FISH]).
• Participant must have received and progressed on or are intolerant to all therapies known to confer overall survival benefit, including at least one line of endocrine + CDK4/6 inhibitor therapy AND one line of cytotoxic such as chemotherapy and/or antibody drug conjugates (ADCs).
• Participant must be a woman ≥ 22 years old and must be able to understand and sign an informed consent form.
• Participant must have a life expectancy of at least 3 months.
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
• it is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of childbearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session.
• Participants must meet one of the following:

• Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy)
• Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation.
• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence methods such as calendar, ovulation, symptothermal, or post ovulation tracking are not acceptable.
• Not in a sexual relationship in which they may become pregnant (i.e. same-sex relationship)
• If they are of childbearing potential, agree to use at least one method of contraception. Withdrawal is not an acceptable contraceptive method.

Exclusion Criteria

• Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
• Participants that are taking any other investigational drugs.
• Participants that are pregnant or breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.
• Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).
• Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study.
• Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device.

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Barbara Ann Karmanos Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Hadeel Assad

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Hadeel Assad, M.D.

Role: CONTACT

Phone: 1-800-527-6266

Email: assadh@karmanos.org

Other Identifiers

2025-043

Identifier Type: -

Identifier Source: org_study_id